Inducing Infringement – Is “Skinny Labelling” a Thing of the Past?

“Skinny label” cases traditionally considered the inclusion of a patented use within the “indication” section of a generic/biosimilar drug manufacturer’s product monograph. As patentees may not be able to rely heavily on direct infringement of use claims, the focus was on indirect infringement (inducement). Recent inducing infringement decisions seem to consider product monographs more broadly. This panel discusses how the inducing infringement analysis has evolved and the current state of skinny labelling case law in Canada.

Benjamin Reingold Bennett Jones LLP (Toronto)
David Yi Norton Rose Fulbright Canada LLP (Toronto)
Sarah Burg Foley Hoag LLP (Boston)
Moderator: Kelly Zhang Belmore Neidrauer LLP 


Intellectual Property Institute of Canada
360 Albert Street, Suite 550
Ottawa, Ontario K1R 7X7 Canada
613-234-0516 |


Institut de la propriété intellectuelle du Canada
360, rue Albert, bureau 550
Ottawa, Ontario K1R 7X7 Canada
613-234-0516 |

back to top